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Abstract 
Chemokines and their receptors collectively orchestrate the trafficking of leukocytes in normal 
immune function and inflammatory diseases. Different chemokines can induce distinct responses 
at the same receptor. In comparison to monocyte chemoattractant protein-1 (MCP-1/CCL2), the 
chemokines MCP-2/CCL8 and MCP-3/CCL7 are partial agonists of their shared receptor CCR2, a key 
regulator of monocyte/macrophage trafficking. Using chimeras of MCP-1 and MCP-3, we have 
identified the chemokine N-terminal region as being the primary determinant of the binding and 
signaling selectivity of these two chemokines at CCR2. Analysis of CCR2 mutants showed that the 
chemokine N-terminus interacts with the major subpocket in the transmembrane helical bundle of 
CCR2 as distinct from the interactions of some other chemokines with the minor subpockets of their 
receptors. These results suggest the major subpocket as an excellent target for development of 
CCR2 small molecule inhibitors. 
 
One Sentence Summary: Interactions of different chemokine N-termini with the transmembrane 
bundle of a shared receptor induce distinct signaling responses. 
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Introduction 
G protein-coupled receptors (GPCRs) are the largest family of transmembrane receptors and 
the targets of numerous therapeutics. Many GPCRs can be activated by a variety of different natural 
and/or synthetic agonists, which may give rise to distinct signaling outcomes. Whereas partial 
agonists evoke a submaximal response relative that of a full agonist even at concentrations that 
saturate all receptor sites, biased agonists can display pathway-dependent efficacy, activating 
certain pathways to the relative exclusion of others (1, 2). 
The recent flood of GPCR structures has yielded a wealth of new information regarding 
receptor architecture, ligand binding sites and G protein binding sites as well as some details of the 
conformational changes associated with receptor activation (3-5). Consequently, we can now begin 
to identify the structural mechanisms by which different agonists induce distinct signaling outcomes. 
Herein we describe an analysis of the structural features underlying differential activation of a 
chemokine receptor by its cognate chemokine ligands. 
Chemokine receptors are GPCRs expressed in leukocyte membranes, whereas chemokines are 
small, soluble proteins expressed in tissues during normal immune surveillance or in response to 
injury or infection. Activation of chemokine receptors by their cognate chemokines induces 
leukocyte migration into, and accumulation in, the chemokine-expressing tissues (6-8), a hallmark 
feature of the inflammatory response. Consequently, chemokine receptors are potential 
therapeutic targets in a wide range of inflammatory diseases (9). There is increasing evidence that 
cognate chemokines can differentially activate their shared receptors, including examples of partial 
agonism (10-14) and biased agonism (15, 16). 
CCR2 is the major chemokine receptor on monocytes and macrophages, cells that play central 
roles in the pathology of atherosclerosis, obesity and type 2 diabetes. In atherosclerosis, CCR2 
activation by the monocyte chemoattractant proteins MCP-1 (systematic name CCL2), MCP-2 (CCL8) 
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and MCP-3 (CCL7) induces recruitment of monocytes from the blood into arterial walls, where they 
differentiate into macrophages and contribute to development of atherosclerotic plaques (17). In 
obesity, CCR2 activation by MCP chemokines is associated with macrophage infiltration into adipose 
tissue and induction of insulin resistance (18). Considering the importance of CCR2 in inflammatory 
diseases, there is strong motivation to understand its mechanism of activation by its cognate 
chemokine ligands. 
Although their distinct biological functions are not fully understood, the MCP chemokines are 
differentially expressed in response to Th1 versus Th2 inflammatory stimuli and can have distinct 
temporal patterns of expression, suggesting that they may also activate distinct cellular responses 
via their shared receptor (19, 20).  In support of this possibility, Berchiche et al. have shown that 
cognate chemokines for CCR2 display differences in their efficacies of activation of both β-arrestin 
and G protein-mediated signaling pathways (13). Here, we verify that this differential signaling can 
be attributed to partial agonism rather than biased agonism and we use a variety of chemokine 
chimeras and CCR2 mutants to identify key structural elements of both the chemokines and 
receptor that mediate this differential activation. Data are interpreted in light of the recent 
structures of chemokine-receptor complexes (21, 22), yielding insights towards the design of 
selective pharmacological agents. 
 
Results 
MCP chemokines have different efficacies and affinities at CCR2 
We monitored activation of CCR2 by MCP chemokines using one proximal, non-amplified 
measure of receptor activation (recruitment of β-arrestin 2) and two downstream, amplified signals 
(inhibition of cAMP formation and phosphorylation of ERK1/2). The three chemokines induced 
recruitment of β-arrestin 2 (β-arr2) with different potencies and significantly different maximal 
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effects, Emax (Fig. 1A, Table 1); relative to MCP-1, the Emax of MCP-2 and MCP-3 were 23 ± 3% and 56 
± 4%, respectively. In the two amplified signaling assays, the three chemokines exhibited the same 
maximal effect as each other but significantly different potencies, and higher potencies than in the 
β-arr2 assay (Fig. 1, B and C; Table 1). The order of potencies between the three agonists in the 
amplified assays was the same as the order of their maximal effects in the proximal assay. Moreover, 
the same rank order of binding affinities was also observed in a radioligand binding assay (Fig. 1D; 
Table 1). These results are in good agreement with the effects of MCP chemokines reported 
previously (13). 
Analysis of our data using an approach based upon the operational model of agonism (23, 24) 
indicated that the MCP chemokines did not display biased agonism (fig. S1; Table S1) but instead 
that MCP-2 and MCP-3 are partial agonists of CCR2, relative to MCP-1. The data in Fig. 1, A to D 
highlight two underlying differences in the receptor interactions of the MCP chemokines. First, the 
three chemokines have different affinities for CCR2 (Fig. 1D). Second, the three chemokines have 
different maximal effects in the proximal β-arr2 recruitment assay (Fig. 1A). Although the rank order 
of these maximal effects is the same as the rank order of affinities for the three chemokines, the 
maximal effects occur at ligand concentrations at which the receptor is fully occupied so they do 
not result from differences in binding affinity. Instead, they indicate that the ligands have distinct 
efficacies, i.e. distinct intrinsic abilities to induce the receptor-mediated response.   
In the more amplified assays (inhibition of cAMP and ERK1/2 phosphorylation), the maximal 
effects of full and partial agonists are indistinguishable (the signals are amplified to the full capacity 
of the pathway even when the activated state of the receptor is only partially populated). In such 
assays the relative potency of the chemokines is determined by both the affinities of the 
chemokines for CCR2 and their relative efficacies (25). Indeed, the order of potency in the cAMP 
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and pERK assays is consistent with both their relative affinities for the receptor and their relative 
Emax values in the proximal assay (Fig. 1, A to D). 
An important consequence of partial agonism in the context of the β-arrestin assay is that 
subsequent regulatory processes, such as receptor internalization, will also be submaximally 
engaged by the action of partial agonists. In agreement with the work of Berchiche et al. (13), both 
MCP-2 and MCP-3, at saturating concentrations, caused very limited internalization of CCR2, 
whereas MCP-1 induced significant internalization (Fig. 1E). These differences correlate with the 
relative efficacies of the three chemokines. 
Considering the robust and consistent differences observed among the MCP chemokines for 
CCR2 binding and activation (Fig. 1), this system is ideally suited for investigation of the structural 
features influencing the relative affinities and efficacies of different chemokines at their shared 
receptor, as described below. 
 
The chemokine N-terminal tail is a major determinant of affinity and efficacy 
Mutational and structural studies have previously identified three regions of chemokines that 
interact with receptors (26-29). The so-called “N-loop” (a ~12 residue sequence between the 
conserved CC or CXC motif and the first β-strand ) and the β3 region (third β-strand and preceding 
turn) form the two sides of a shallow groove that binds to the flexible N-terminal tail of the receptor. 
The N-terminal region of the chemokine (preceding the CC or CXC motif) penetrates into the 
transmembrane helical bundle of the receptor. To identify the structural elements of MCP 
chemokines that contribute to partial versus full agonism and to relative CCR2 affinity, we prepared 
a series of chimeras in which these three functionally important regions are swapped between MCP-
1 and MCP-3 (Fig. 2); MCP-3, rather than MCP-2, was chosen primarily because it is more closely 
related to MCP-1, thereby simplifying the interpretation of chimera experiments (see 
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Supplementary Material). Each chimera is named according to the parental chemokine from which 
it is derived followed by a sequence of three numbers representing the origin of the N-terminal, N-
loop and β3 elements, respectively; for example, MCP1-133 is a chimera derived from MCP-1 and 
containing the N-terminal region of MCP-1, the N-loop of MCP-3 and the β3 region of MCP-3. Each 
chimera was expressed as inclusion bodies in E. coli, refolded and purified. 1H NMR spectra (Fig. 2 
and fig. S2) are similar to those of the wild type (WT) chemokines, indicating that the chimeras are 
well folded and adopt the expected native 3D structures. 
To assess the contributions of the three chemokine structural regions to CCR2 binding affinity, 
we measured the abilities of the MCP chimeras to compete with 125I-MCP-1 binding to CCR2. As 
shown in Fig. 3, A and E, and Table 2, MCP-1 has 10-fold higher affinity than MCP-3 at CCR2. 
Replacement of the N-terminus of MCP-1 with that of MCP-3 caused a decrease in affinity such that 
this chimeric chemokine displayed an affinity comparable to that of MCP-3.  Similarly, replacement 
of the N-terminus of MCP-3 with that of MCP-1 generated a chimeric chemokine with comparable 
affinity to that of MCP-1.  These results clearly indicate that the N-terminus of MCP-1 has a 
significant role in determining its higher affinity as compared to MCP-3. 
In contrast to the clear contribution of the N-terminal region to binding selectivity, 
replacement of the N-loop and/or β3 region of MCP-1 with that of MCP-3 did not affect the CCR2 
binding affinity.  Similarly, substitution of the β3 region of MCP-3 with that of MCP-1 had no 
significant effect on affinity.  However, replacement of the N-loop of MCP-3 by that of MCP-1, alone 
or in combination with the β3 region (chimeras MCP3-313 and MCP3-311) reduced the affinity for 
CCR2. This is consistent with the previous findings that the N-loop is a major contributor to CCR2 
binding but also suggests that the ability of the N-loop to interact favorably with the receptor is 
dependent on the background scaffold in which it is located. Notably, subsequent introduction of 
the MCP-1 N-terminal region, to give the MCP3-111 chimera, increased CCR2 affinity 100-fold 
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(relative to MCP3-311), again highlighting the importance of the N-terminus as a determinant of 
chemokine affinity at CCR2.  
To assess the contributions of the three chemokine structural regions to the efficacy of CCR2 
activation, we measured the abilities of the chemokine chimeras to stimulate β-arr2 recruitment 
(Fig. 3B). As described above, MCP-3 displayed a significantly lower maximal effect than MCP-1 (Fig. 
1A; Fig. 3, B and E). Replacement of the N-loop and/or the β3 region of MCP-1 with those of MCP-3 
(or vice versa) caused no significant changes in Emax. In contrast, replacement of the N-terminus of 
MCP-1 with that of MCP-3, alone or in combination with replacement of both the N-loop and β3 
region, caused a significant decrease in maximal effect compared to MCP-1, to a level comparable 
to the maximal effect of MCP-3. This vital role of the N-terminus in determining chemokine efficacy 
at CCR2 was further highlighted in the reciprocal chimeras whereby integration of the N-terminus 
of MCP-1 into an MCP-3 background (MCP3-133 and MCP3-111) resulted in a significant increase in 
the maximal effect.  Interestingly, the Emax values of these two chimeras were greater than that of 
wild type MCP-1, again emphasizing that the background chemokine “context” plays an additional 
role in determining efficacy at CCR2. 
In addition to the above Emax values, our data also report on the potencies of the chemokine 
chimeras in the β-arr2 recruitment. Although, we observed no significant differences in the 
potencies (Fig. 3E; Table 2), the order of potencies is consistent with the order of binding affinities 
and of Emax values described above. Similarly, at a more amplified signaling endpoint of ERK1/2 
phosphorylation (Fig. 3, C and E), replacing the N-terminus of MCP-1 by that of MCP-3 caused a 
decrease in potency whereas replacing the N-terminus of MCP-3 by that of MCP-1 caused an 
increase in potency, although these effects did not reach significance (Fig. 3E; Table 2). 
In the ERK1/2 phosphorylation assay, the two wild type chemokines and most chimeras 
displayed similar maximal effects (Fig. 3E; Table 2), However, chimera MCP3-111 displayed a 
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significantly lower Emax than wild type MCP-3 in the ERK1/2 phosphorylation assay despite exhibiting 
a significantly higher Emax than MCP-3 in the β-arr2 assay. Further analysis (fig. S3 and Table S3) 
indicated that this chimera displayed significant biased agonism relative to WT MCP-3, suggesting 
that the three substituted regions of the chemokines may act cooperatively to influence signaling 
efficacy in a pathway specific manner.  
From these data it is clear that the N-termini of MCP-1 and MCP-3 have important roles in 
determining the relative affinities of the different chemokines at CCR2 as well as their relative 
efficacies. Based on these results, we predicted that the chimeric chemokines in which the N-
terminal regions were swapped would have altered abilities to induce CCR2 internalization.  As 
expected, MCP1-311 lost its ability to internalize the CCR2, while the reciprocal N-terminal swap 
chimera (MCP3-133) was now able to induce receptor internalization (Fig. 3D). 
 
Identification of CCR2 residues contributing to differential chemokine binding and agonism 
In light of the above observations that the chemokine N-terminal regions contribute to both 
the affinity of CCR2 binding and the efficacy of CCR2 activation, we sought to identify the residues 
within CCR2 with which the chemokine N-terminal regions interact. Recent structures of two 
chemokine-receptor complexes (21, 22) have confirmed that the N-terminal regions of chemokines 
penetrate into the transmembrane (TM) helical bundles of their receptors, where they presumably 
induce structural rearrangement and signaling. To identify specific residues of CCR2 that contribute 
to these interactions, we characterized chemokine binding and activation for a series of CCR2 
mutants. Guided by a homology model of the MCP-1:CCR2 complex, which was based on the 
reported structure of receptor CXCR4 cross-linked to chemokine vMIP-II (21), we designed six point 
mutants and four double mutants at positions pointing towards the interior of the TM bundle (Fig. 
S4; Table 3). Each mutant was stably expressed in FlpIn HEK-293 cells with an N-terminal cMyc 
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epitope tag, enabling measurement of cell surface expression. After confirming that all mutants 
were expressed at similar levels to WT CCR2 (Table 3), we evaluated the affinity of chemokine 
binding at each mutant receptor. We extended this evaluation to measure the potency and efficacy 
of MCP-1 and MCP-3 at the mutant receptors using ERK1/2 phosphorylation as a convenient 
measurement of receptor activation that does not require the use of modified receptor fusion 
constructs or overexpression of signaling effectors.  
None of the mutations significantly changed the affinities for MCP-1 or MCP-3 compared to 
WT CCR2 (Table 3; Fig. 4A; fig. S5). However, comparison of the relative affinities of MCP-1 and MCP-
3 at the different mutants was more revealing. MCP-3 displays a 10-fold lower affinity than MCP-1 
at the WT CCR2. While this difference in affinity was maintained at the majority of the CCR2 mutants, 
no such difference in affinity was observed at the R206A and Y259F mutations. Therefore, the 
difference in affinity between MCP-1 and MCP-3 appears to be governed, at least in part, by these 
two residues. 
As shown previously at WT CCR2, MCP-1 displays a significantly higher potency than MCP-3. 
This difference in potency was maintained across most mutants, in accordance with the relative 
affinities for the two ligands (Fig. 4B; fig. S5). Nevertheless, mutant Y259F displayed increased 
potency for both chemokines; double mutant I263A/N266A displayed significantly increased 
potency for MCP-1 (p = 0.003) and a smaller, but not significant, increase for MCP-3; and D284A 
showed a significant potency increase for MCP-1 but not MCP-3 (Fig. 4B). 
Although the potencies of ERK1/2 phosphorylation correlate well with CCR2 binding affinities 
for the wild type chemokines (Fig. 1), there is a poor correlation between affinity and potency 
comparing the same chemokine across the set of CCR2 mutants (fig. S6, A and B). This suggests that 
some of the mutations influence the mechanism of receptor signaling rather than ligand binding. To 
further explore this possibility, we examined the maximal effects induced by the two chemokines in 
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the ERK1/2 phosphorylation assay (Fig. 4C; fig. S5; fig. S6C). CCR2 mutants Y120F, R206A, 
E270A/F272A and E291A displayed significantly lower Emax values for both MCP-1 and MCP-3 as 
compared to WT CCR2. Interestingly, the maximal effect of MCP-1 but not MCP-3 was significantly 
reduced at the I263A/N266A mutant. Conversely, the double mutant N199A/T203A displayed a 
significantly reduced Emax for MCP-3 but not MCP-1. Finally, the mutation K34A caused an increase 
in Emax relative to WT for MCP-1 and a similar trend was observed for MCP-3. It should be noted that 
the cell surface expression levels for all mutants was not significantly different. Thus, these changes 
in maximal signaling likely reflect the roles of these residues in conformational rearrangement of 
CCR2 coupled to ERK1/2 signaling pathways.  
 
Discussion 
Humans and other mammals express a complex array of chemokines and receptors that 
collectively orchestrate the trafficking of leukocytes, a central feature of the innate immune 
response. The existence of multiple chemokines that activate the same receptor was previously 
thought to represent functional redundancy. However, recent results, including observations of 
partial agonism (10-14) and biased agonism (15, 16) increasingly suggest that different chemokines 
are able to alter receptor responses in a subtle and selective manner. In this study, we have begun 
to elucidate the structural features underlying the partial agonism of MCP chemokines at their 
shared receptor CCR2. 
Numerous previous structure-function studies of chemokines have identified residues within 
the N-loop and β3 region as being critical for binding interactions and residues within the N-terminal 
region as being critical for receptor activation (26-29). These conclusions are encapsulated by the 
two-site model, which postulates that chemokines first use their N-loop/β3 residues (chemokine 
site 1; CS1) to bind to the receptor N-terminus (receptor site 1; RS1) and subsequently the 
 12 
chemokine N-terminus (chemokine site 2; CS2) activates the receptor by binding to its 
transmembrane helices (receptor site 2; RS2), inducing conformational changes and cellular 
signaling (29). The presumption that binding and activation occur in two discrete steps rather than 
concomitantly is not derived from kinetic measurements but instead deduced from indirect 
evidence such as the ability of N-terminally truncated chemokines to bind strongly without 
activating their receptors (30, 31). Recent structures of two chemokine-receptor complexes (21, 22) 
helped to validate key features of the two-site model but also suggested that the two sites may not 
be completely independent. As discussed in a recent, comprehensive review (32), a number of 
additional observations have also suggested that elaborations of the two-site model may be 
necessary. In summary, although the two-site model is broadly supported by structural and 
mutational data and has served as a useful guide for mechanistic studies, it is too simplistic to 
account for such subtle observations as partial or biased agonism. 
The structure-function relationships of MCP-1 have been thoroughly examined in a seminal 
study by Handel and coworkers (27, 28). MCP-1 residues T10 (N-terminal region, immediately 
preceding the CC motif), Y13 and R24 (N-loop), K35 (“30s” loop) and K49 (β3 region) make 
substantial contributions to CCR2 binding affinity and N-terminal residues I5 and V9 of MCP-1 
contribute to signaling via CCR2. Almost all of the MCP-1 residues shown to play key roles in CCR2 
binding or activation are identical in MCP-3. Thus, the interactions of these residues are likely to 
also occur for MCP-3 and do not account for the differences in the CCR2 binding affinity or efficacy 
of MCP-1 and MCP-3. In good agreement with the previous observations of MCP-1 mutants and the 
two-site model, our β-arr2 recruitment data for MCP1-311 and MCP3-133 indicate that the 
chemokine N-terminal region is the major selectivity determinant of receptor activation manifested 
by changes in the intrinsic efficacy of these different chemokines. However, surprisingly, our 
analysis of MCP-1/MCP-3 chimeras also identified the N-terminal region as being the primary 
determinant of the binding selectivity of these two chemokines to CCR2. Residues within this region 
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were not previously found to contribute to binding affinity, with the sole exception of T10 (27), 
which is identical in MCP-1 and MCP-3. Our results are consistent with the prevailing model that the 
majority of binding affinity for both chemokines is provided by residues in the N-loop and β3 regions. 
However, it now appears that these regions contribute equally to the CCR2 binding affinities of both 
chemokines whereas the N-terminal region of MCP-1 contributes more binding energy compared 
to the N-terminal region of MCP-3, resulting in the higher binding affinity of MCP-1. In the two-site 
model, the chemokine N-terminal region corresponds to CS2, which is considered to be the key 
determinant of receptor activation but not to play a role in the initial binding step. Our results 
suggest an extension of the two-site model such that CS2/RS2 interactions contribute either to the 
initial binding step or to the formation of a more stable complex subsequent to initial binding but 
prior to (or concomitant with) receptor activation. 
To identify receptor residues that interact with the N-terminal regions of MCP-1 and/or MCP-
3, we mutated residues in CCR2 whose side chains are predicted to point towards the interior of the 
transmembrane helical bundle. Several of the mutants displayed altered chemokine binding.  In 
particular, mutation of R2065.42 or Y2596.51 (superscripts indicate Ballesteros-Weinstein numbering 
(33)) completely abolished the ~10-fold binding selectivity of CCR2 for MCP-1 over MCP-3. These 
residues form a closely packed cluster with residues Y1203.32, I2636.55 and E2917.39 in a region where 
TM helices 3, 5, 6 and 7 come together, previously defined as the “major subpocket” of the receptor 
(Fig. 5, A to C) (34). In support of the contribution of this structural region to binding, mutation of 
I263 (in the I263A6.55/N266A6.58 double mutant) slightly reduced affinity for MCP-3 and mutation of 
E2917.39 slightly reduced affinity for both MCP-1 and MCP-3 (Table 3). Although we cannot exclude 
the possibility that this cluster of amino acids influences chemokine binding via an indirect, allosteric 
mechanism, these residues are adjacent to the extreme N-terminus of the bound chemokine in our 
homology model (Fig. 5, A to C), suggesting that they interact directly with the chemokine ligands. 
This conclusion is supported by a recent exhaustive mutagenesis study of CXCR4 defining a similar 
 14 
cluster of signal “initiation residues” adjacent to the N-terminus of CXCL12 (35). Notably, in the 
complex of vMIP-II with CXCR4 from which our homology model was derived, the N-terminus of 
vMIP-II points slightly away from these residues into the “minor subpocket” of CXCR4 (Fig. 5, D and 
E) (21). Our data suggest that the interactions of the CCR2 major subpocket with the chemokine N-
terminus play a critical role in stabilizing the chemokine-receptor complex and in determining the 
relative affinities of MCP-1 and MCP-3 at their shared receptor. 
Among the CCR2 mutations that reduced chemokine binding affinity, the Y259F and 
I263A/N266A mutations surprisingly caused increased potency of MCP-1 and/or MCP-3. This lack of 
correlation between potency and affinity can be rationalized by considering the possible 
interactions of these residues in the chemokine-receptor complex prior to undergoing the 
conformational change required for activation (the inactive state) and after this conformational 
change (the active state). Our affinity measurements were performed in the presence of guanine 
nucleotides and therefore are likely to probe interactions in the (G protein-uncoupled) inactive state 
whereas the potency of ERK1/2 phosphorylation is likely to be more sensitive to interactions in the 
active state. We suggest that the Y259F and I263A/N266A mutations disrupt interactions in the 
inactive state but favor the transition to the active state, thereby enhancing potency. In contrast, 
the R206A and E291A mutants displayed decreased affinity and decreased efficacy of ERK1/2 
phosphorylation without any significant change in potency.  Disruption of these residues may alter 
the structure of the active state such that it is no longer well coupled to ERK signaling effectors. 
Several CCR2 mutations influenced ERK1/2 phosphorylation without affecting chemokine 
binding affinity. In particular, the D284A7.32 mutation enhanced the potency of ERK phosphorylation 
in response to MCP-1 and the K34A1.28 mutation enhanced the efficacy of ERK phosphorylation in 
response to both chemokines. These two residues are located adjacent to each other and form a 
salt bridge in our homology model (Fig. 5B). We propose that these residues do not contribute 
directly to ligand interactions but instead stabilize the inactive state of the receptor by interacting 
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with each other and/or with other residues on adjacent TM helices. Disruption of these interactions 
may therefore facilitate the transition to the active state, albeit at the expense of destabilizing the 
unbound receptor structure. 
 
Conclusion 
We have shown that the distinct affinities and efficacies of CCR2 activation by MCP 
chemokines can be primarily attributed to the interactions of the chemokine N-terminal region, 
suggesting an elaboration of the two-site model in which the chemokine N-terminus contributes to 
binding interactions prior to receptor activation. By analysis of CCR2 mutants, we have identified a 
cluster of CCR2 residues nestled between transmembrane helices 3, 5, 6 and 7 that appears to be 
the key binding site for the chemokine N-terminus. Considering that the equivalent residues of 
chemokine receptor CCR5 comprise a substantial part of the binding site for the anti-HIV drug 
maraviroc (Fig. 5, F and G) (36), our results suggest that this site within CCR2 may also be a suitable 
target for future development of small molecule inhibitors with potential applications in 
atherosclerosis, obesity/diabetes and other macrophage-associated inflammatory diseases. 
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Materials and Methods  
Details are provided in the Supplementary Material. 
Wild type and chimeric chemokines 
Chimeras of human chemokines MCP-1 (obligate monomeric mutant P8A) and MCP-3 (Fig. 2) 
consisted of the sequence of one chemokine with one or more of the following three regions 
replaced by the corresponding residues from the other chemokine: N-terminus (residues 1-10); N-
loop (residues 12-24); β3 region (residues 46-52). For N-loop substitutions, residue V22 (MCP-1) or 
K22 (MCP-3) was not replaced and, for β3 region substitutions, residue I46 (MCP-1) or K46 (MCP-3) 
was not replaced because these residues are buried in the hydrophobic core and mutation would 
be expected to disrupt the protein fold.  Genes encoding the chimeras were constructed by 
recursive PCR and ligated into pET28a plasmid for expression. Amino acid sequences of the 
chemokines and chimeras are listed in fig. S7. All chemokines and chimeras were expressed and 
purified as described by Tan et al (37). Protein identity was confirmed by MALDI-TOF mass 
spectrometry (Table S3). 1H NMR spectra were recorded at 25 °C and 600 MHz. 
CCR2 mutants 
A homology model of human CCR2 bound to human MCP-1 was constructed based on the crystal 
structure of CXCR4 bound (and cross-linked) to the viral chemokine vMIP-II (PDB code: 4RWS) (21). 
Individual CCR2 residues or pairs of residues were selected for mutation based on their locations 
and orientations in the predicted chemokine binding site on the interior of the TM helical bundle. 
The wild type and mutant c-Myc-FLAG-CCR2 constructs in pcDNA5/FRT/TO (37) were stably 
transfected into HEK293 Flp-In TRex cells for all use in all cell-based assays. CCR2 expression was 
measured using anti-c-Myc ELISA as described (38). 
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CCR2 binding and activation assays 
Competitive binding assays were performed as described by Zweemer et al. (39) using membranes 
prepared from the CCR2-expressing cells. Recruitment of β-arrestin-2 to CCR2 was assessed in 
HEK293 Flp-In TRex transiently transfected with CCR2-RLuc8 and β-arrestin-2-YFP as described (40). 
Phosphorylation of ERK1/2 in c-Myc-FLAG-CCR2 HEK293 FlpIn TRex cells was measured using the 
AlphaScreen® SureFire® p-ERK 1/2 (Thr202/Tyr204) Assay Kit (PerkinElmer, TGR biosciences). The 
ability of ligands to inhibit forskolin-induced cAMP production was assessed in c-Myc-FLAG-CCR2 
HEK293 FlpIn TRex cells transiently transfected to express the CAMYEL cAMP BRET biosensor (38). 
Data analysis and statistics 
All data points represent the mean and error bars represent the standard error of the mean (SEM) 
of at least three independent experiments. All data from concentration-response curves were 
normalized and fitted and statistics were determined using Prism 6.0 (GraphPad Software Inc., San 
Diego, CA). All parameters were estimated as logarithms. Multiple T test comparison with Holm-
Sidak correction or one way ANOVA were used as stated in Figure Legends. Significance is defined 
as * for p< 0.05, ** for p<0.01 and *** for p < 0.001 for the comparison graphs. 
 
Supplementary Materials 
Detailed Materials and Methods 
Fig.  S1. Biased agonism for wild type chemokines 
Fig. S2. NMR spectra of chemokine chimeras 
Fig. S3. Biased agonism of chemokine chimeras 
Fig. S4. Positions of CCR2 mutations on homology model 
Fig. S5. Concentration response curves for CCR2 mutants 
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Fig. S6. Graphical comparisons of chemokine binding and activation parameters for CCR2 mutants 
Fig. S7. Amino acid sequences of chemokine chimeras 
Table S1. Biased agonism analysis for wild type chemokines 
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 β-arrestin recruitment cAMP inhibition ERK 1/2 phosphorylation 
125I-MCP1 
binding 
pEC50 Emax pEC50 Emax pEC50 Emax pKi 
MCP-1 8.32 ± 0.06 100  ± 2 9.10  ± 0.21 100  ± 9 9.16  ± 0.24 100  ± 10 10.60  ± 0.08 
MCP-2 7.24 ± 0.26 * 23  ± 3 *** 7.34  ± 0.14 *** 113 ± 9 7.58  ± 0.15 *** 119  ± 9 8.88  ± 0.14 *** 
MCP-3 7.33 ± 0.15 * 56  ± 4 ** 8.47  ± 0.16 * 109  ± 9 8.09  ± 0.19 *** 116  ± 10 9.50  ± 0.12 *** 
 
Table 1: Potency, efficacy and affinity of the different MCP chemokines at the hCCR2 receptor in β-arrestin recruitment, Fsk-induced cAMP inhibition, 
pERK and radioligand binding assays. β-arrestin 2 recruitment was assessed using BRET in FlpInTRex 293 cells transiently transfected with CCR2-RLuc8 
and β-arr2-YFP. Inhibition of cAMP was measured using a BRET-based cAMP sensor transiently transfected in c-Myc-FLAG-hCCR2 FlpInTRex 293 cells. 
ERK1/2 phosphorylation was measured 3 min after chemokine stimulation in c-Myc-FLAG-hCCR2 FlpInTRex 293 cells. 125I-MCP-1 competition binding 
was measured in membrane preparations of c-Myc-FLAG-hCCR2 FlpInTRex 293 cells. pEC50 and pKi values are the negative log of EC50 and Ki values, 
respectively, in molar units. Emax values are reported as a percentage of the value for MCP-1. Data are mean ± SEM from 3-4 experiments performed 
in triplicate. * P<0.05, ** P<0.01, *** P<0.001, one-way ANOVA with Dunnett’s multiple comparison test. Emax is shown relative to that observed with 
MCP-1. 
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 β-arrestin recruitment ERK 1/2 phosphorylation 
125I-MCP1 
binding 
pEC50 Emax pEC50 Emax pKi 
MCP-1 8.00 ± 0.13 0.100 ± 0.006^^^ 7.87 ± 0.32 37.8 ± 3.4 10.67 ± 0.18 ^^ 
MCP1-311 7.30 ± 0.21 0.067 ± 0.006* 6.84 ± 0.17 40.3 ± 3.2 9.90 ± 0.18 
MCP1-131 8.32 ± 0.13 0.11 2± 0.006^^^ 7.64 ± 0.26 43.7 ± 3.7 10.53 ± 0.17 ^^ 
MCP1-113 8.12 ± 0.13 0.111 ± 0.006^^^ 7.58 ± 0.46 46.7 ± 6.8 10.68 ± 0.16 ^^ 
MCP1-133 8.45 ± 0.27 0.103 ± 0.009^^ 7.86 ± 0.42 36.4 ± 5.0 10.84 ± 0.16 ^^ 
MCP1-333 7.82 ± 0.58 0.034 ± 0.009*** 6.95 ± 0.29 24.0 ± 3.1 10.02 ± 0.17 
MCP-3 7.63 ± 0.17 0.060 ± 0.004** 7.21 ± 0.31 34.3 ± 4.0 9.50 ± 0.19 ** 
MCP3-133 8.24 ± 0.11 0.0135 ± 0.005^^^ 8.12 ± 0.33 25.9 ± 2.3 10.36 ± 0.14 
MCP3-313 7.17  ± 0.22 0.051 ± 0.006*** 7.43 ± 0.27 33.1 ± 3.0 7.45 ± 0.23 ***, ^^ 
MCP3-331 7.65 ± 0.22 0.056 ± 0.006** 7.66  ± 0.36 21.7 ± 2.3* 8.77 ± 0.33 *** 
MCP3-311 7.13 ± 0.39 0.050 ± 0.010*** 7.87 ± 0.14 40.0 ± 1.6 7.32 ± 0.32 ***, ^^ 
MCP3-111 7.61 ± 0.20 0.134 ± 0.010^^^ 7.99 ± 0.36 21.3 ± 2.4* 9.80 ± 0.17 
 
Table 2: Potency, efficacy and affinity of the MCP chemokine chimeras at the hCCR2 receptor in β-arrestin recruitment, pERK and radioligand binding 
assays. 125I-MCP-1 competition binding was measured in membrane preparations of c-Myc-FLAG-hCCR2 FlpInTRex 293 cells. β-arrestin 2 recruitment 
was assessed using BRET in FlpInTRex 293 cells transiently transfected with CCR2-RLuc8 and β-arr2-YFP. ERK1/2 phosphorylation was measured 3-5 
min after chemokine stimulation in c-Myc-FLAG-hCCR2 FlpInTRex 293 cells. pEC50 and pKi values are the negative log of EC50 and Ki values, respectively, 
in molar units. Emax values are relative to the positive control. Data are mean ± SEM from 3-4 experiments performed in triplicate. * P<0.05, **,^^ 
P<0.01, ***,^^^ P<0.001, compared to MCP-1 or MCP-3 respectively; one-way ANOVA with Dunnett’s multiple comparison text. 
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Mutation Location
# Cell surface 
expression pKi 
pERK1/2 
pEC50 
pERK1/2 
Emax (% FBS) 
   MCP-1 MCP-3 MCP-1 MCP-3 MCP-1 MCP-3 
WT  100 ± 3 10.82 ± 0.18 9.64 ± 0.19^ 8.01  ± 0.23 7.30  ± 0.23 38.9 ± 3 35.5 ± 4.5 
K34A TM1 (1.28) 119 ± 12 10.42 ± 0.27 9.70 ± 0.42 8.41 ± 0.24 7.70 ± 0.23 55.5 ± 2.5*** 45.0 ± 2.8 
Y120F TM3 (3.32) 118 ± 13 11.15 ± 0.18 9.65 ± 0.26^ 7.92 ± 0.32 7.58 ± 0.33 25.4 ± 2** 16.6 ± 1.6*** 
V187/V189A ECL2 108 ± 6 11.36 ± 0.29 9.85 ± 0.32^ 7.99 ± 0.26 7.28 ± 0.23 30.5  ± 2 30.8 ±2.3 
N199A/T203A TM5 (5.35/5.39) 116 ± 7 11.42 ± 0.29 10.17 ± 0.47 7.66 ± 0.23 7.35 ± 0.33 32.8 ± 2 20.2 ± 2.3
** 
R206A TM5 (5.42) 112 ± 7 10.29 ± 0.22 10.12 ± 0.33 8.25 ± 0.31 7.81 ± 0.34 11.0 ± 0.8*** 14.8 ± 2.5*** 
Y259F TM6 (6.51) 99 ± 6 10.44 ± 0.23 10.20 ± 0.14 8.78 ± 0.36* 8.57 ± 0.26** 31.9 ± 1.7 39.3 ± 1.7 
I263A/N266A TM6 (6.55/6.58) 107 ± 8 10.79 ± 0.24 8.99 ± 0.17
^ 9.46 ± 0.39** 8.22 ± 0.38 24.7 ± 2*** 36.9 ± 3.4 
E270A/F272A TM6/ECL3 99 ± 13 11.68 ± 0.39 10.06 ± 0.31^ 7.36 ± 0.20 7.36 ± 0.20 22.3 ± 1.3*** 22.1 ± 1.5** 
D284A TM7 (7.32) 104 ± 5 10.91 ± 0.16 9.52 ± 0.25^ 8.83 ± 0.40** 7.80 ± 0.18 34.9 ± 2 39.1 ± 1.9 
E291A TM7 (7.39) 107 ± 9 10.26 ± 0.24 9.03 ± 0.22^ 7.66 ± 0.40 7.09 ± 0.48 27.9 ± 3* 12.1 ± 2.2*** 
 
Table 3: Characterization of CCR2 mutants. Cell surface expression was measured by anti c-Myc ELISA in c-Myc-FLAG-hCCR2 FlpInTRex 293 cells 
(expressed as a percentage of WT receptor). Affinity (pKi) of MCP-1 and MCP-3 for WT or mutant CCR2 was measured by 125I-MCP-1 competition 
binding with cell membrane preparations. Potency (pEC50) and efficacy (Emax) of MCP-1 and MCP-3 for WT or mutant CCR2 in ERK1/2 phosphorylation 
was measured 3 min after chemokine stimulation in c-Myc-FLAG-hCCR2 FlpInTRex 293 cells. pEC50 and pKi values are the negative log of EC50 and Ki 
values, respectively, in molar units. Emax values are relative to the positive control. Data are mean ± SEM from 3-4 experiments performed in triplicate. 
For radioligand binding, ^ P<0.05, compared to MCP-1 for each mutant, multiple t-test. For ERK1/2 phosphorylation, * P<0.05, ** P<0.01, *** P<0.001, 
 27 
compared to CCR2 WT, one-way ANOVA with Dunnett’s multiple comparison test. # Ballesteros and Weinstein numbering of TM residues shown in 
parentheses (33). 
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Figure Legends 
Figure 1. MCP chemokines display different efficacies and affinities at the hCCR2. (A) β-arrestin 2 
recruitment was assessed using BRET in FlpInTRex 293 cells transiently transfected with CCR2-RLuc8 
and β-arr2-YFP. (B) Inhibition of cAMP was measured using a BRET-based cAMP sensor transiently 
transfected in c-Myc-FLAG-hCCR2 FlpInTRex 293 cells. (C) ERK1/2 phosphorylation was measured 3 
min after chemokine stimulation in c-Myc-FLAG-hCCR2 FlpInTRex 293 cells. (D) 125I-MCP-1 
competition binding was measured in membrane preparations of c-Myc-FLAG-hCCR2 FlpInTRex 293 
cells. (E) Time-course of receptor internalization in response to 100 nM of MCPs detected in c-Myc-
FLAG-hCCR2 FlpInTRex 293 cells by whole cell anti c-Myc ELISA. Data are means ± SEM from 3-5 
experiments performed in triplicate. * P<0.05, ** P<0.01, *** P<0.001, **** P<0.0001 one-way 
ANOVA with Dunnett’s multiple comparison test. 
Figure 2. Design and structural validation of MCP-1/MCP-3 chimeras. (A) Aligned sequences of 
MCP-1 and MCP-3 with the three regions swapped in the chimeras indicated by boxes. Symbols 
above the residue labels indicate those previously found to be important in CCR2 binding (*) or 
activation (^) (27, 28). (B) The structure of MCP-1 (pdb code: 1dok) highlighting the regions swapped 
in the chimeras. (C) Nomenclature and schematic diagrams of the chimeras with regions from MCP-
1 and MCP-3 in blue and red, respectively. (D) Upfield (methyl) region of the 1H NMR spectra of WT 
and chimeric chemokines, showing well-dispersed peaks indicative of correct folding. 
Figure 3. The N-terminal tail of MCP-1 and MCP-3 is a major determinant of affinity and efficacy. 
125I-MCP-1 competition binding, β-arrestin 2 recruitment BRET and ERK1/2 phosphorylation were 
assessed for MCP-1 and MCP-3 chimeric chemokines (top/blue and bottom/red, respectively).  (A) 
125I-MCP-1 competition binding was measured in membrane preparations of c-Myc-FLAG-hCCR2 
FlpInTRex 293 cells. (B) β-arrestin 2 recruitment was assessed using BRET in FlpInTRex 293 cells 
transiently transfected with CCR2-RLuc8 and β-arr2-YFP. (C) ERK1/2 phosphorylation was measured 
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3 min after chemokine stimulation in c-Myc-FLAG-hCCR2 FlpInTRex 293 cells. (D) CCR2 
internalization upon stimulation with Vehicle, 100 nM MCP-1, MCP1-311, MCP-3 or MCP3-133 for 
60 min was measured in c-Myc-FLAG-hCCR2 FlpInTRex 293 cells by whole cell anti c-Myc ELISA. Data 
are means ± SEM from 3-5 experiments performed in triplicate. * P<0.05, ** P<0.01, one-way 
ANOVA with Dunnett’s multiple comparison text. (E) Affinity (pKi), potency (pEC50) and efficacy 
(Emax) for WT and chimeric chemokines in 125I-MCP-1 competition binding, β-arrestin 2 recruitment 
BRET and ERK1/2 phosphorylation. Data are means ± SEM from 3-5 experiments performed in 
triplicate. * P<0.05, **,^^ P<0.01, ***,^^^ P<0.001, ****,^^^^ P<0.0001 compared to MCP-1 or 
MCP-3 respectively; one-way ANOVA with Dunnett’s multiple comparison text. 
Figure 4. Identification of CCR2 residues contributing to MCP-1 and MCP-3 binding and agonism. 
125I-MCP-1 competition binding and ERK1/2 phosphorylation were assessed for MCP-1 and MCP-3 
at the wild type (WT) and mutant CCR2 expressed in FlpInTRex 293 cells.  (A) Affinity (pKi) of MCP-1 
(blue) and MCP-3 (red) for WT or mutant CCR2 measured by 125I-MCP-1 competition binding with 
cell membrane preparations. Right/grey panel: differences in affinity between MCP-1 and MCP-3 at 
each mutant. ^ P<0.05, compared to the difference observed at the WT and * P<0.05, compared to 
zero (i.e. indicating difference between chemokines), multiple t-test. (B) Potency (pEC50) of MCP-1 
(blue) and MCP-3 (red) for WT or mutant CCR2 in ERK1/2 phosphorylation. Right/grey panel: 
differences in potency between MCP-1 and MCP-3 at each mutant receptor. * P<0.05, ** P<0.01 
compared to the difference observed at the WT one-way ANOVA with Dunnett’s multiple 
comparison test. (C) Efficacy (Emax) of MCP-1 (blue) and MCP-3 (red) for WT or mutant CCR2 in 
ERK1/2 phosphorylation. Right/grey panel; ratio of efficacies between MCP-1 and MCP-3 at each 
mutant. * P<0.05, ** P<0.01, *** P<0.001, **** P<0.0001 compared to ratio observed at the WT, 
one-way ANOVA with Dunnett’s multiple comparison test. Data are means ± SEM from 3-5 
experiments performed in triplicate. 
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Figure 5. The major subpocket of CCR2 recognizes the N-termini of MCP chemokines. (A) Full and 
(B) detailed side views and (C) end-on view (from the extracellular perspective) showing the 
homology model of CCR2 bound to MCP-1. CCR2 transmembrane helices are coloured salmon (TM1), 
orange (TM2), pale yellow (TM3), pale green (TM4), aquamarine (TM5), light blue (TM6) and violet 
(TM7); other receptor residues are in grey. Side chain sticks are shown for several residues discussed 
in the text in darker shades of the same colours as the helices in which they are located. MCP-1 is 
in teal with the N-terminus in rainbow colours from blue (residue 1) to red (residue 10). In (C) the 
major (M) and minor (m) subpockets are labelled in red. (D) and (E) The CXCR4:vMIP-II complex (pdb 
code: 4rws) displayed as in (B) and (C), respectively. (F) and (G) The CCR5:maraviroc complex (pdb 
code: 4mbs) displayed as in (B) and (C), respectively; maraviroc is shown as sticks coloured by 
element (C, green; N, blue; O, red). 
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